Kelly Financial Services’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-66
Closed -$1.55K – 153
2024
Q2
$1.55K Hold
66
– – ﹤0.01% 615
2024
Q1
$1.9K Hold
66
– – ﹤0.01% 607
2023
Q4
$2.17K Hold
66
– – ﹤0.01% 572
2023
Q3
$1.84K Hold
66
– – ﹤0.01% 554
2023
Q2
$2.25K Hold
66
– – ﹤0.01% 539
2023
Q1
$1.99K Hold
66
– – ﹤0.01% 528
2022
Q4
$1.86K Hold
66
– – ﹤0.01% 513
2022
Q3
$2.17K Hold
66
– – ﹤0.01% 493
2022
Q2
$2.08K Hold
66
– – ﹤0.01% 496
2022
Q1
$3.03K Hold
66
– – ﹤0.01% 482
2021
Q4
$4.04K Buy
+66
New +$4.56K ﹤0.01% 470

Other funds holding ARKG

Kelly Financial Services's ARKG Position: Q3 2024 in Review

Kelly Financial Services sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2024, closing a stake of 66 shares — an estimated $1.55K sold.

Kelly Financial Services first reported a position in ARKG in Q4 2021 and held it in 11 quarters. The position peaked at $4.04K in Q4 2021. 240 funds tracked by Wall St. Rank hold ARKG as of Q3 2024.

  • Kelly Financial Services reported no remaining ARK Genomic Revolution ETF position as of Q3 2024 after selling out during the quarter.
  • Kelly Financial Services sold 66 ARK Genomic Revolution ETF shares in Q3 2024, an estimated $1.55K.
  • Kelly Financial Services first reported a position in ARK Genomic Revolution ETF in Q4 2021 and held it in 11 quarters.
  • Kelly Financial Services's ARK Genomic Revolution ETF position peaked at $4.04K in Q4 2021.
  • 240 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2024.

Based on Kelly Financial Services's 13F filing for Q3 2024, filed 9 Oct 2024.